Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.

美纳里尼基金会

该基金会成立于 1976 年...

GO TO SITE

美纳里尼在亚太地区

搜索我们的公司

主要品牌

最新动态

August 15 2022

Menarini and SciClone Establish License and Collaboration Agreement for Vaborem® in China to Expand Treatment Options for Antimicrobial Resistant Infections

Read More
August 11 2022

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Read More
August 02 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Read More
July 22 2022

Australian sports stars shine at XXVI Fair Play Menarini International Awards

Read More
July 21 2022

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

Read More